Discover 1,705 paid clinical trials in Detroit, Michigan. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,705
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
for
Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis,
Location: Detroit MI, Ann Arbor MI, Cleveland OH, Independence OH,
Sponsor: Kartos Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT06479135
Phase3, Recruiting
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Location: Detroit MI, Canton OH, Fairfax VA, St Louis MO
Sponsor: Sairopa B.V.
Sex: All
Age: 18+
Code: NCT05856981
Phase1, Recruiting
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
for
Melanoma
Location: Detroit MI, Ann Arbor MI, Cleveland OH, London,
Sponsor: Regeneron Pharmaceuticals
Sex: All
Age: 18+
Code: NCT06246916
Phase3, Recruiting
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
for
Locally Advanced Solid Tumor
Location: Detroit MI, Chicago IL, Zion IL, Urbana IL, Fairfax VA,
Sponsor: Tango Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT05732831
Phase1, Phase2, Recruiting
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Location: Detroit MI, Columbus OH, Toronto, Chicago IL,
Sponsor: Nuvalent Inc.
Sex: All
Age: 12+
Code: NCT05118789
Phase1, Phase2, Recruiting
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
for
Multiple Myeloma
Location: Detroit MI, Southfield MI, Novi MI, Ann Arbor MI,
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 18+
Code: NCT05552222
Phase3, Recruiting
Utilization of Educational Interventions in Completion of Genetic Testing in Black Patients With High-Risk Prostate Cancer
for
Prostate Cancer
Location: Detroit MI
Sponsor: Henry Ford Health System
Sex: Male
Age: 18+
Code: NCT05958082
Recruiting
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
for
Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer,
Location: Detroit MI, Louisville KY, Atlanta GA, Omaha NE,
Sponsor: Inhibrx Biosciences, Inc
Sex: All
Age: 18+
Code: NCT04198766
Phase1, Phase2, Recruiting
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
for
Head and Neck Squamous Cell Carcinoma (HNSCC)
Location: Detroit MI, Columbus OH, Evanston IL, Edgewood KY,
Sponsor: Regeneron Pharmaceuticals
Sex: All
Age: 18+
Code: NCT06769698
Phase2, Recruiting
Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
for
Small Cell Lung Cancer ( SCLC ),
Location: Detroit MI
Sponsor: Bindu R Potugari
Sex: All
Age: 18+
Code: NCT07339059
Phase2, Recruiting
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
for
Small-cell Lung Cancer
Location: Detroit MI, Cleveland OH, Mayfield Heights OH, Akron OH,
Sponsor: Zai Lab (Shanghai) Co., Ltd.
Sex: All
Age: 18+
Code: NCT07218146
Phase3, Recruiting
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer
for
Small Cell Lung Cancer
Location: Detroit MI, Los Angeles CA
Sponsor: SciTech Development, Inc.
Sex: All
Age: 18+
Code: NCT06922539
Phase1, Recruiting
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
for
Non-Small-Cell Lung Cancer,
Location: Detroit MI, Columbus OH, Brampton, Toronto, Chicago IL,
Sponsor: ArriVent BioPharma, Inc.
Sex: All
Age: 18+
Code: NCT07185997
Phase3, Recruiting
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)